Deal Snapshot
SECURA BIO ACQUIRES RIGHTS TO FARYDAK FROM NOVARTIS
Thursday 14 March 2019

Nevada, US-based commercial stage biopharmaceutical company Secura Bio, Inc. has acquired the global rights to Farydak (panobinostat) from Novartis for treating multiple myeloma, the company said.

Farydak has received FDA accelerated approval for use in patients with multiple myeloma, and on August 28, 2015 it was approved by the European Medicines Agency for the same use. Farydak has received marketing authorisation in 53 countries to date for the treatment of patients with multiple myeloma.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 14/03/2019
Target: Global rights to Farydak (panobinostat)
Country: USA
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing:
Status: Closed
Vendor: Novartis
Buyer: Secura Bio, Inc
Comment:
Terms of the deal were not disclosed

Options